Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma

This phase I trial studies the side effects and best dose of ibrutinib and palbociclib in treating patients with previously treated mantle cell lymphoma. Ibrutinib and palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Palbociclib may also help ibrutinib work better by making cancer cells more sensitive to the drug.

Study Overview

• Status: Active, not recruiting
• Conditions: Recurrent Mantle Cell Lymphoma
• Intervention / Treatment: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Palbociclib; Drug: Ibrutinib

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate the safety of ibrutinib plus PD 0332991 (palbociclib) in patients with previously treated mantle cell lymphoma (MCL) and select the recommended phase 2 dose schedule.

SECONDARY OBJECTIVES:

I. To estimate the toxicity profile of ibrutinib plus PD 0332991 (palbociclib). II. To estimate the overall response rate (ORR) and complete response (CR) rates.

III. To estimate the progression-free survival (PFS). IV. To estimate the response duration (RD).

LABORATORY OBJECTIVES:

I. To evaluate the genomic profile of MCL cells pre-treatment and at relapse. II. To estimate the pharmacokinetic profile of ibrutinib when given concurrently with PD 0332991 (palbociclib).

III. To evaluate the level of cell-free tumor deoxyribonucleic acid (DNA) over time in conjunction with response to therapy.

IV. To evaluate the presence of circulating MCL cells over time.

OUTLINE: This is a dose-escalation study.

Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 2 years.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • New York
    • New York, New York, United States, 10065
      • NYP/Weill Cornell Medical Center
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • UNC Lineberger Comprehensive Cancer Center
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University Comprehensive Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed mantle cell lymphoma as defined by the World Health Organization; all patients must have either t(11;14) by karyotype or fluorescent in-situ hybridization (FISH) or positive immunohistochemistry for cyclin D1
• Subjects must have measurable disease defined as at least one tumor lesion of at least 1.5 cm or a peripheral blood CD5+, CD19+ lymphocyte count of at least 5,000 cells/uL

• Subjects must have received at least one prior treatment regimen

  • Subjects that have received a prior BTK inhibitor or CDK4/6 inhibition are ineligible
  • Subjects that have undergone prior allogeneic stem cell transplantation will only be eligible if the transplant occurred at least 1 year prior to study entry, the patient is no longer taking any immunosuppressive therapy, and there are no significant ongoing transplant-related adverse effects
  • Subjects must not have received chemotherapy =< 21 days prior to first administration of study treatment, monoclonal antibody =< 6 weeks prior to first administration of study treatment, and/or radiotherapy or other investigational agents =< 4 weeks prior to first administration study treatment unless the subjects' tumor has progressed on the previous therapy and the investigator believes that the patient should not postpone further therapy and, all treatment-related toxicities have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5 =< grade 1; subjects may be receiving equivalent to prednisone at a maximum dose of 20 mg/day orally
• Subjects must be age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
• Patients must have normal organ and marrow function, independent of transfusion or growth factor support within 14 days before enrollment; patients should not receive growth factors or transfusions for at least 7 days prior to the first dose of study drug, with the exception of pegylated GCSF (pegfilgrastim) and darbepoetin, which require at least 14 days prior to screening and enrollment
• Absolute neutrophil count (ANC) >= 750 cells/uL (within 14 days before enrollment)
• Platelets >= 50,000 cells/uL (within 14 days before enrollment)
• Total bilirubin =< 1.5 times upper limit of normal unless due to Gilbert's disease (within 14 days before enrollment)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times upper limit of normal (within 14 days before enrollment)
• Calculated creatinine clearance >= 30 mL/min by Cockcroft-Gault (within 14 days before enrollment)
• Corrected QT interval (QTc) =< 480 ms (within 14 days before enrollment)
• Prothrombin time (PT)/international normalized ratio (INR) < 1.5 times upper limit of normal (within 14 days before enrollment)
• Partial thromboplastin time (PTT) < 1.5 times upper limit of normal (within 14 days before enrollment)
• The effects of ibrutinib and PD 0332991 (palbociclib) on the developing human fetus are unknown; for this reason and because tyrosine kinase inhibitors as well as other therapeutic agents used in this trial may be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; female patients who are of non-reproductive potential include the following: post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); female patients of childbearing potential must have a negative serum pregnancy test upon study entry; male and female patients who agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug
• Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ibrutinib administration; subjects should be offered the opportunity to bank sperm or eggs prior to initiation of study drug
• Subjects with currently active, clinically significant hepatic impairment (> moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification)
• Subjects requiring daily corticosteroids at a prednisone equivalent of > 20 mg daily should not be enrolled; if corticosteroids can be discontinued (or reduced to < 20 mg per day or prednisone equivalent), the discontinuation or dose reduction should be done at least 7 days prior to the first dose
• Subjects should be willing to undergo a research related biopsy prior to treatment and at the time of progression
• Subjects must give informed consent and must be willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other procedures

Exclusion Criteria:

• Subjects with known or suspected central nervous system (CNS) involvement are not eligible
• Subjects with serologic status reflecting active viral hepatitis B or C infection are not eligible; subjects that are positive for hepatitis B core antibody positive hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR-positive patients will be excluded.)
• Subjects with uncontrolled human immunodeficiency virus (HIV) are not eligible; controlled HIV is defined as a CD4 count > institutional lower limit of normal and no current co-infection; uncontrolled HIV is all other HIV infection; note that patients with controlled infection should be allowed to participate only if they are not receiving prohibited cytochrome P450 (CYP) interactive medications
• Subjects unable to swallow capsules or with disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption, such as malabsorption syndrome, resection of the stomach or small bowel, partial or complete bowel obstruction, or symptomatic inflammatory bowel disease are not eligible
• Subjects with uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are not eligible; recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of the study drugs
• Subjects with uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP) resulting in declining platelet or hemoglobin levels within the 4 weeks prior to first dose of study drug are not eligible
• Patients with transfusion-dependent thrombocytopenia are not eligible
• Subjects with acute coronary syndrome within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities are not eligible; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
• Subjects with a history of stroke or intracranial hemorrhage within 6 months prior to enrollment are not eligible

• Subjects with a history of malignancy are not eligible with the exception of the following:

  • Malignancy treated within curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician
  • Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease
  • Adequately treated cervical carcinoma in situ without current evidence of disease
• Female subjects that are pregnant or breastfeeding are not eligible
• Subjects that have received anticoagulation therapy with warfarin or equivalent vitamin K antagonists within the last 28 days are not eligible
• Subjects with a bleeding diathesis (e.g., von Willebrand's disease or hemophilia) are not eligible
• Subjects that have undergone major surgery within 4 weeks prior to the first dose of study drug are not eligible
• Subjects receiving other investigational agents are not eligible
• Subjects who received a strong CYP3A inhibitor within 7 days prior to the first dose of study drug, or patients who require continuous treatment with a strong CYP3A inhibitor are not eligible
• Subjects receiving systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc.) within 28 days of the first dose of study drug are not eligible
• Subjects that have been vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug are not eligible

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (ibrutinib, palbociclib); Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Laboratory Biomarker Analysis; Correlative studies; Other: Pharmacological Study; Correlative studies; Drug: Palbociclib; Given PO; Other Names: Ibrance; 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one; PD 0332991; PD 332991; PD 991; PD-0332991; Drug: Ibrutinib; Given PO; Other Names: PCI-32765; Imbruvica; BTK Inhibitor PCI-32765; CRA-032765

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recommended phase II dose of the combination of ibrutinib and palbociclib	Will be defined as the highest dose level at which no more than 1/6 patients present with a dose limiting toxicity (DLT). DLT will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Up to 28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate (ORR)	Will be evaluated according to the revised response criteria of the International Working Group.	Up to 2 years
Complete response (CR) rate	Will be evaluated according to the revised response criteria of the International Working Group.	Up to 2 years
Partial response rate	Will be evaluated according to the revised response criteria of the International Working Group.	Up to 2 years
Progression-free survival (PFS)	Estimated and plotted by Kaplan-Meier survival analysis and 95% confidence intervals will be calculated using Greenwood's formula. Log-rank test will be applied to compare the difference between survival curves with two-sided significance level of 0.05.	Time from entry onto study until first documentation of objective tumor progression or death due to any cause, whichever occurs first, assessed up to 2 years
Response duration (RD)	Estimated and plotted by Kaplan-Meier survival analysis and 95% confidence intervals will be calculated using Greenwood's formula. Log-rank test will be applied to compare the difference between survival curves with two-sided significance level of 0.05.	Time from when criteria for response (CR or partial response [PR]) are met, until first documentation of relapse or progression, assessed up to 2 years
Incidence of toxicities	Will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. A listing of all adverse events (AEs) including detailed information for each AE will be presented. The number and percentage of patients who experienced any: AE, serious adverse events (SAE), treatment-related AE, and treatment-related SAE will be summarized. AE data will be presented by dose for all cycles, cycle 1 only and cycles > 1, as appropriate. Additional summaries of AE data and of other safety data will be presented in tabular and/or graphical format and summarized descriptively, as appropriate.	Up to 2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Genetic alterations	Sequencing data will be evaluated for mutations and copy number variations (CNV) and the status of wild type and alterations will be assigned. Fisher's exact test will be used to assess the association between genetic alterations and response to study drugs. A moderated t-test will be applied to the transformed ribonucleic acid sequencing data to assess the expression difference between wild-type and altered genes. The Benjamini-Hochberg procedure will be used to adjust the p value and use the false discovery rate 10% as the cutoff to declare significance.	Up to 2 years

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Peter Martin, Weill Medical College of Cornell University

Publications and helpful links

General Publications

• Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457. Epub 2019 Jan 28. Erratum In: Blood. 2019 Sep 12;134(11):908.

Study record dates

Study Major Dates

• Study Start (Actual): May 20, 2014
• Primary Completion (Actual): June 25, 2018
• Study Completion (Estimated): January 20, 2025

Study Registration Dates

• First Submitted: June 9, 2014
• First Submitted That Met QC Criteria: June 9, 2014
• First Posted (Estimated): June 10, 2014

Study Record Updates

• Last Update Posted (Estimated): February 5, 2024
• Last Update Submitted That Met QC Criteria: February 2, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Mantle-Cell; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Palbociclib
• Other Study ID Numbers: NCI-2014-01202 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); UM1CA186704 (U.S. NIH Grant/Contract); UM1CA186712 (U.S. NIH Grant/Contract); P30CA013696 (U.S. NIH Grant/Contract); K24CA201524 (U.S. NIH Grant/Contract); 1403014853; 9534 (Other Identifier: CTEP)